Login to Your Account



PCSK9 inhibitors: a race to become the next new cholesterol blockbuster

By Ulrike Jahnke
Thomson Reuters

Thursday, February 27, 2014
LONDON ­– PCSK9 inhibitors have been hailed the most important new heart drugs in years, with resulting multibillion-dollar sales potential.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription